Patient-specific devices and population-level evidence: evaluating therapeutic interventions with inherent variation
- 159 Downloads
Designing and manufacturing medical devices for specific patients is becoming increasingly feasible with developments in 3D printing and 3D imaging software. This raises the question of how patient-specific devices can be evaluated, since our ‘gold standard’ method for evaluation, the randomised controlled trial (RCT), requires that an intervention is standardised across a number of individuals in an experimental group. I distinguish several senses of patient-specific device, and focus the discussion on understanding the problem of variations between instances of an intervention for RCT evaluation. I argue that, despite initial appearances, it is theoretically possible to use RCTs to evaluate some patient-specific medical devices. However, the argument reveals significant difficulties for ensuring the validity of such trials, with implications for how we should think about methods of evidence gathering and regulatory approaches for these technologies.
KeywordsMedical device Regulation Randomised controlled trial Personalised medicine 3D printing
My thanks to Robert Sparrow, Wendy Rogers, David Wotton, Tajanka Mladenovska, and the anonymous referees for this journal, for their comments on previous drafts. The funding was provided by Australian Research Council (Grant No. CE140100012)
- Bargar, W. L. 1989. Shape the implant to the patient: A rationale for the use of custom-fit cementless total implants. Clinical Orthopedics and Related Research 249: 73–78.Google Scholar
- Food and Drug Administration (FDA). 2014. Custom device exemption: Guidance for industry and Food and Drug Administration staff. Rockville, MD: US Department of Health and Human Services.Google Scholar
- Gilbert, F., C. D. O’Connell, T. Mladenovska, and S. Dodds. 2017. Print me and organ? Ethical and regulatory issues emerging from 3D bioprinting in medicine. Science and Engineering Ethics 1–19.Google Scholar
- Grant, P., A. Aamodt, J. A. Falch, and L. Nordsletten. 2005. Differences in stability and bone remodeling between a customized uncemented hydroxyapatite coated and a standard cemented femoral stem. A randomized study with use of radiostereometry and bone densitometry. Journal of Orthopedic Research 23 (6): 1280–1285.Google Scholar
- Medical Research Council (2008) Developing and evaluating complex interventions: New guidance, http://www.mrc.ac.uk/complexinterventionsguidance.
- Mustafa, F. A. 2017. Notes on the use of randomised controlled trials to evaluate complex interventions: Community treatment orders as an illustrative case. Journal of Evaluation in Clinical Practice 23(1): 185–192.Google Scholar
- Nazarian, R., H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. K. Lee, N. Attar, H. Sazegar, T. Chodon, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas, and R. S. Lo. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.CrossRefGoogle Scholar
- Nieuwenhuis, J. B., E. Irving, K. O. Rengerink, E. Lloyd, I. Goetz, D. E. Grobbee, P. Stolk, R. H. H. Groenwold, and M. Zuidgeest. 2016. Pragmatic trial design elements showed a different impact on trial interpretation and feasibility than explanatory elements. Journal of Clinical Epidemiology 77: 95–100.CrossRefGoogle Scholar
- Straussman, R., R. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, and T. Golub. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500–504.CrossRefGoogle Scholar
- Therapeutic Goods Administration (TGA). No date. Custom-made medical devices (fact sheet). Available at: https://www.tga.gov.au/custom-made-medical-devices.
- Thorpe, K. E., M. Zwarenstein, A. D. Oxman, S. Treweek, C. D. Furberg, D. Altman, S. Tunis, E. Bergel, I. Harvey, D. Magid, and K. Chalkidou. 2009. A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. Journal of Clinical Epidemiology 62: 464–475.CrossRefGoogle Scholar
- Wallace, G. G., R. Cornock, C. O’Connell, S. Beirne, S. Dodds, and F. Gilbert. 2014. 3D bioprinting: Printing parts for bodies. Wollongong: ARC Centre of Excellence for Electromaterials Science. https://3dbioprint.creatavist.com/3dbioprinting.
- Wilson, T. R., J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, and J. Settleman. 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505–509.CrossRefGoogle Scholar